During Monday’s Morning trade, Shares of EMC Corporation (NYSE:EMC), gained 0.96% to $27.33.
ClusterHQ, The Container Data People, declared integration between ClusterHQ’s Flocker container data administration software and EMC Corporation’s (NYSE: EMC) EMC® ScaleIO® and EMC XtremIO™ storage solutions. As a result, developers and operations (DevOps) teams can architect and manage high performance, reliable, scalable, and cost-effective persistent storage backends for Docker-based applications. EMC collaborated with ClusterHQ to develop pluggable storage drivers for ScaleIO and XtremIO solutions that enable flexible and portable shared storage for Docker. Organizations can easily take advantage of the portability and massive per-server density benefits inherent in containers, while still deploying EMC’s advanced storage solutions. Through this collaboration, users will now have easy, direct access to ScaleIO and XtremIO storage volumes at the container level.
By enabling stateful Docker containers to be easily migrated between servers, or racks, Flocker enables app developers and DevOps teams to deploy and run multi-container distributed applications that comprise databases, queues and key value stores. Many modern applications are built from both stateless and stateful microservices; Flocker makes it simple and practical for entire applications, counting their data, to be containerized and achieve true portability between development, staging and production. The integration with XtremIO’s all-flash array is designed to allow enterprises to centralize local storage for Docker containers and provide superior performance, failover and high availability capabilities, in addition to backup and restore capability for both the container and its associated storage.
ClusterHQ builds container data administration software that enables broader adoption of container technology in production environments. DevOps teams worldwide rely on ClusterHQ’s open source Flocker software to meet the data portability requirements of distributed, microservices-based applications.
EMC Corporation develops, delivers, and supports information infrastructure and virtual infrastructure technologies, solutions, and services. It offers enterprise storage systems and software deployed in storage area networks (SAN), networked attached storage (NAS), unified storage combining NAS and SAN, object storage, and/or direct attached storage environments, in addition to provides a portfolio of backup products that support a range of enterprise application workloads.
Shares of Mylan N.V. (NASDAQ:MYL), inclined 0.61% to $72.06, during its current trading session.
Pulmatrix (Nasdaq:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, recently declared that it has reached an ex-U.S. development agreement with Mylan N.V., one of the world’s leading global pharmaceutical companies. The agreement is for PUR0200, a clinical stage bronchodilator therapy being studied for chronic obstructive pulmonary disease (COPD) and the first small molecule formulation from the company’s novel iSPERSE™ inhaled dry powder technology. PUR0200 is under development as a once-daily therapy in a capsule-based dry powder inhaler (DPI).
PUR0200 contains a long-acting muscarinic agent (LAMA) being studied for the treatment of COPD and current clinical development is focused on pharmacokinetic bioequivalence in Europe. According to IMS Health, global sales of LAMA monotherapies for COPD are about $5 billion for the 12 months ending Dec. 31, 2014 with $1.5 billion in sales outside the U.S. Continued development work under the agreement will initiate in 2015.
Robert Clarke, CEO of Pulmatrix, said: “Our agreement with Mylan for the development of PUR0200 is a major step for Pulmatrix and the continued development of our iSPERSE technology. At the current stage of development of PUR0200 and aims of the program, Mylan is the ideal partner to bring this product forward for COPD patients.”
Under the terms of the agreement, Pulmatrix will lead the development work and pharmacokinetic clinical study with collaborative support from Mylan. Mylan has retained an option for PUR0200 ex-U.S. based on successful completion of the clinical study. Financial terms of the agreement are confidential.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
Finally, Cypress Semiconductor Corporation (NASDAQ:CY), gained 0.28%, and is now trading at $12.72.
Cypress Semiconductor Corporation, declared that its President and Chief Executive Officer, T.J. Rodgers, sent the updated Superior Proposal to Jimmy S.M. Lee, Executive Chairman of the Board of Directors of Integrated Silicon Solution, Inc.
Cypress Semiconductor Corporation provides mixed-signal programmable solutions, semiconductor memories, and integrated semiconductor solutions worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
